New commercial boss for Notts pharma firm

Quotient Clinical, the Ruddington-based drug development services provider, has appointed Azhar Kalim as chief commercial officer.

Kalim will lead the enhanced commercial team in a new role, with a focus on supporting Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions.

Quotient has recently bought SeaView Research, a specialist early phase clinical pharmacology business, and QS Pharma, a small molecule formulation development and manufacturing business.

Mark Egerton, chief executive officer, said: “Azhar has over 25 years’ experience in the drug development services sector, as a leader in expanding research capabilities and creating unique service offerings to the biopharma industry. Quotient takes pride in being a highly customer focused organisation and we are delighted to welcome Azhar in this vital role at an exciting point in the company’s development. I look forward to working with him on a continued journey of growth and success.”

Kalim said: “Quotient’s integrated capabilities offer a unique solution to our clients. I am delighted to be joining a dynamic and rapidly expanding business, and I look forward to working with the team to build long term, sustainable, and strategic relationships with our customers.”